Skip to main content
SpringerLink
Log in

Evaluation of the Efficacy of Chloroquine and Hydroxychloroquine in the Treatment of Individuals with COVID-19: A Systematic Review

  • Conference paper
  • First Online:
XXVII Brazilian Congress on Biomedical Engineering (CBEB 2020)

Part of the book series: IFMBE Proceedings ((IFMBE,volume 83))

Included in the following conference series:

  • 12 Accesses

Abstract

This work consists of a literature review that aims to evaluate the effects and efficacy of two drugs used to treat individuals with COVID-19: chloroquine (CQ) and hydroxychloroquine (HCQ). Both drugs have demonstrated antiviral activity against the new coronavirus in in vitro tests. However, there is currently no strong evidence from well-designed controlled studies of COVID-19 therapies tested in humans. In addition, the evidence on the effects of drugs on patients is extremely limited. The search for evidence was made from five chosen databases, and after applying the criteria for inclusion and exclusion of articles, 5 publications were obtained, which represented the basis for the construction of this work. We concluded that, in relation to CQ, no favorable outcomes were found in relation to its use. High doses of this drug can increase lethality due to the prolongation of the QT interval, and lower doses could not estimate evident benefits in infected patients. Assessing the results of HCQ, it can be concluded that more studies are needed to effectively use this drug in the treatment of individuals with COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 509.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Xu Z, Shi L, Wang Y et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 4:420–422. https://doi.org/10.1016/S2213-2600(20)30076-X

    Article  Google Scholar 

  2. Sohrabi C, Alsafi Z, O’Neill N et al (2020) World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 76:71–76. https://doi.org/10.1016/j.ijsu.2020.02.034

    Article  Google Scholar 

  3. COVID, CDC; TEAM, Response (2020) Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020 MMWR Morb Mortal Wkly Rep 12:343–346 https://doi.org/10.15585/mmwr.mm6912e2

  4. Rodriguez-Morales A, Cardona-Ospina J, Gutiérrez-Ocampo G et al (2020) Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis Travel Med Inf Dis 101623:45–50. https://doi.org/10.1016/j.tmaid.2020.101623

  5. Jean S, Hsueh P (2020) Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther (in press). https://doi.org/10.1080/14787210.2020.1771181

  6. Kapoor K, Kapoor A (2020) Role of Chloroquine and Hydroxychloroquine in the treatment of COVID-19 infection-a systematic literature review Medrxiv 1–17 https://doi.org/10.1101/2020.03.24.20042366

  7. Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 3:269–271. https://doi.org/10.1038/s41422-020-0282-0

    Article  Google Scholar 

  8. Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 10–282 https://doi.org/10.1093/cid/ciaa237

  9. Esposito S, Noviello S, Pagliano P (2020) Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med 2:198–211

    Google Scholar 

  10. Dybå T, Dingsøyr T (2008) Empirical studies of agile software development: a systematic review. Inf Softw Technol 50:833–859. https://doi.org/10.1016/j.infsof.2008.01.006

    Article  Google Scholar 

  11. Borba M, Val F, Sampaio V et al (2020) Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 study). MedRxiv. https://doi.org/10.1101/2020.04.07.20056424

    Article  Google Scholar 

  12. Gautret P, Lagier J, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949 https://doi.org/10.1016/j.ijantimicag.2020.105949

  13. Chen J, Liu D, Liu L et al (2020) A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban 2:215–219

    Google Scholar 

  14. Chen Z, Hu J, Zhang Z et al (2020) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. https://doi.org/10.1101/2020.03.22.20040758

    Article  Google Scholar 

  15. Mahévas M, Tran V, Roumier M et al (2020) Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. https://doi.org/10.1136/bmj.m1844

    Article  Google Scholar 

Download references

Acknowledgements

To the research support agencies: FAPEMIG, CAPES and CNPq. A. A. Pereira is Fellow of CNPq, Brazil (310911/2017-6).

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Faculty of Electrical Engineering, Federal University of Uberlândia, Centre for Innovation and Technology Assessment in Health (NIATS), Avenue João Naves de Ávila, Uberlândia, MG, 2121, Brazil

    L. C. Mendes, J. Ávila & A. A. Pereira

Authors
  1. L. C. Mendes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Ávila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Electrical Engineering, Universidade Federal do Espírito Santo, Vitória, Brazil

    Teodiano Freire Bastos-Filho

  2. Department of Electrical Engineering, Universidade Federal do Espírito Santo, Vitória, Brazil

    Eliete Maria de Oliveira Caldeira

  3. Department of Electrical Engineering, Universidade Federal do Espírito Santo, Vitória, Brazil

    Anselmo Frizera-Neto

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Mendes, L.C., Ávila, J., Pereira, A.A. (2022). Evaluation of the Efficacy of Chloroquine and Hydroxychloroquine in the Treatment of Individuals with COVID-19: A Systematic Review. In: Bastos-Filho, T.F., de Oliveira Caldeira, E.M., Frizera-Neto, A. (eds) XXVII Brazilian Congress on Biomedical Engineering. CBEB 2020. IFMBE Proceedings, vol 83. Springer, Cham. https://doi.org/10.1007/978-3-030-70601-2_308

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70601-2_308

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70600-5

  • Online ISBN: 978-3-030-70601-2

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation